alcohol use disorder

Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial with MEAI-based CMND-100 in patients diagnosed with Alcohol Use Disorder (AUD).  The active...

Psychedelics biopharma company FSD Pharma Inc. (NASDAQ: HUGE)’s advisory board has a new member: the iconic entrepreneur and inventor of the infomercial Kevin Harrington. In addition to helping develop its R&D programs as well as product development,...

Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.   This is the first time Awakn, a psychedelics biotech and services provider, will license its protocols...

Awakn Opens Fourth European Clinic, Norway Takes Center Stage Awakn Life Sciences Corp. (OTCQB: AWKNF), a psychedelics biotech company with a near-term focus on Alcohol Use Disorder (AUD), has opened a new clinic providing its proprietary ketamine-assisted psychotherapy (KAP) in the center of...

Calgary-based SABI Mind is the first clinical site to receive approval from the Health Research Ethics Board of Alberta (HREBA) to launch a trial assessing psilocybin-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD). Sponsored by Canadian biotech company Clairvoyant...

Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for its proprietary Ketamine-Assisted Therapy (KAT) to treat severe AUD. The passport...

A new study published in Psychological Medicine shows evidence that legalizing cannabis does not increase substance use disorders or use of other illicit drugs and therefore is not considered a gateway drug. In fact, cannabis may actually reduce alcohol-related problems said researchers...

(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains MEAI is a potent synthetic molecule essentially developed in the...

Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is set to commence this February.  The study, to be led by Prof. Anders Fink-...

What a year for psychedelics! It feels like we’ve come a long way since the sector explode in 2019-2020, the launch of Benzinga's Psyched, companies’ massive migration from private to public, MAPS’ initiation of Phase 3 MDMA trials, the surge of the psilocybin wave,...

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the continuation of its Nordic expansion plans with a new 5-year lease for the opening of a clinic in the center of Trondheim. Awakn’s CEO Anthony Tennyson stated this is a “real momentum growing” for the...

Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule. It will be used in the upcoming Phase 1 clinical trial assessing the treatment of Alcohol Use Disorder (AUD). "Like other addictions,...

A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic.  Awakn Life Sciences Corp. (OTCQB: AWKNF) just signed a five-year lease in Oslo as part of the company’s Nordic expansion plans. Awakn’s new Norwegian...

NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring Awakn’s advanced ketamine-assisted therapy treatment for AUD to Nushama’s New York clinics. They intend to provide sustained...

(Part four of a four-part series - Read part three) The reason why companies offering psychedelic-assisted therapy only use ketamine is that at the moment it is the only one that holds a medical license. While psilocybin and MDMA are showing enormous promise, they are still in ...